A recent meta-analysis reports a high incidence of myocarditis (about 11 times higher than in other therapies) which reaches a mortality rate of about 50% in case of combination therapies (PD1 / PDL-1 associated to CTLA-4 blocking agents) (38, 39). The gene discussed is CTLA4; the disease is myocarditis.